title: PREOS NPS (Allelix/Nycomed).
abstract: NPS Allelix and Nycomed are developing PREOS, an injectable recombinant human parathyroid hormone, for the potential treatment of osteoporosis. In May 2005, NPS filed a market authorization application for PREOS in the US which was accepted for review in July 2005.
authors.affiliation: Royal Liverpool University Hospital, Department of Endocrinology, Liverpool, UK. h.white@ukf.net
authors.forename: Helen
authors.initials: H
authors.lastname: White
authors.forename: Aftab
authors.initials: A
authors.lastname: Ahmad
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004345:Drug Industry; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000819:agonists / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
chemical_list: D010281:Parathyroid Hormone; D011994:Recombinant Proteins